Aytu BioPharma, Inc.AYTUNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank21
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P21
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
2025-52.11%
2024-32.38%
2023-67.66%
2022125.18%
2021226.54%
2020192.32%
2019251.49%
2018-87.57%
2017-78.67%
201684.61%